Metoprololtartrat Hexal (Metoprolol Tartrate)

Metoprolol Tartrate blocks β1‑adrenergic receptors in the heart, preventing catecholamines such as adrenaline from increasing heart rate and contractility. This results in lower cardiac output, reduced myocardial oxygen demand, and a drop in systemic blood pressure, helping to control cardiovascular stress.

The exact dose of Metoprololtartrat Hexal is determined by the prescribing clinician based on the individual’s condition, response, and any comorbidities. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for metoprolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements) and the necessary import documentation.

Metoprolol is a cardio‑selective (β1‑specific) blocker, offering a lower risk of bronchospasm compared with non‑selective agents such as propranolol. Its relatively short half‑life allows flexible dosing, and it is widely studied for post‑MI and heart‑failure indications, making it a common first‑line choice in many guidelines.

Store the tablets below 25 °C in a dry place, preferably in the original container to protect them from moisture and light. Keep out of reach of children and do not use the product after the expiry date printed on the packaging.

Metoprololtartrat Hexal is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, or swelling of the face or throat.

Metoprololtartrat Hexal is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and individuals in cardiogenic shock. Caution is also advised for patients with uncontrolled asthma or severe peripheral vascular disease.